According to Raphael Rostenne, CTO of EyeCarePro, "anything that takes time" has the potential to frustrate patients, ...
Kansas, Tennessee, and Vermont expanded optometric scope in 2026, while vision plan reform and a proposed Medicare fee ...
The FDA approved Lucamzi (ranibizumab-blrz; Xbrane Biopharma), a biosimilar to Lucentis (ranibizumab; Genentech), for neovascular (wet) age-related macular degeneration (AMD) and ...
What to take away on PBM, hormonal eye health, and GLP-1 receptor agonists from this year’s meeting.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry. Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances ...
Host Hamza Shah, OD, MS, FAAO, is joined by Melissa Barnett, OD, FAAO, FSLS, FBCLA, to discuss burnout among US optometrists, inspired by Abbott et al's nationwide survey.
Optometry Times delivers clinical news, practice insights, and research updates by optometrists for optometrists to advance care and patient outcomes.
This week’s top stories include pipeline updates in dry eye, retinitis pigmentosa, contact lens hygiene, and more.
The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 ...
The licaminlimab trial enrolled 176 patients, two-thirds with a TNFR1 variant tied to stronger response. Data expected late 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results